# IQVIA Holdings Inc. (IQV) stock news and updates

As of November 20, 2026. Source: https://www.clearthesis.ai/updates/IQV

## Our view on the IQVIA Holdings Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/IQV

## Latest updates on IQVIA Holdings Inc.

### TD Cowen raised its target for IQVIA to $307

*November 20, 2026 · analyst · significance: minor · signal: positive*

TD Cowen nudged its price target up from $288 following the company's latest results. This move reflects confidence in the business even as the stock has recently fallen. Other analysts have also adjusted their views, bringing the average target across all firms to about $291. While a price target is just an analyst's estimate of where the stock might trade in a year, the buy rating suggests they believe the company's role in managing drug trials remains a strong bet. The stock currently trades well below these targets, reflecting a gap between analyst expectations and recent market movement.

Sources: [TD Cowen](https://thefly.com/ajax/news_get.php?id=4453018)

### Truist Financial raised its price target to $346

*October 30, 2026 · analyst · significance: minor · signal: positive*

Truist Financial raised its price target for the stock from $329 to $346 on Wednesday. This move follows the company's recent earnings report, which showed growing demand for its clinical trial services and a raised forecast for the full year. The new target is well above the current share price of about $266. While several analysts have adjusted their targets recently, the average across the market now sits at roughly $290.

Sources: [Truist Financial](https://thefly.com/ajax/news_get.php?id=4451388)

### We updated our thesis on IQVIA Holdings

*October 28, 2026 · news · significance: notable · signal: neutral*

After IQVIA reported its October results, we updated our fair value and raised our projections for full-year revenue and profit. We have added the quality of the project backlog and the risk of stale contracts to what we track. We also added the profit contributed by minority investments to our analysis of the company's earnings.

### IQVIA beats expectations and raises its full-year outlook

*October 27, 2026 · earnings · significance: major · signal: positive*

IQVIA reported third-quarter earnings of $3.34 per share on revenue of $4.43 billion, both coming in higher than what analysts expected. The company saw growth across its two main businesses: the arm that helps drugmakers run clinical trials and the division that sells healthcare data and analytics. What matters most for the long term is the $3.2 billion in new bookings this quarter, a 15 percent jump from last year. This adds to a massive backlog of signed work that provides a clear view of future revenue. Because the company is bringing in more cash than expected, management raised its financial targets for the full year. This suggests that pharmaceutical companies are still spending heavily on outsourcing their research, which plays directly into IQVIA's scale advantage.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1478242/000162828026067406/0001628280-26-067406-index.htm)

### Stifel Nicolaus raised its target for IQVIA to $303

*October 16, 2026 · analyst · significance: minor · signal: positive*

Stifel Nicolaus raised its price target for IQVIA to 303 dollars, up from its previous target of 276 dollars. This follows a trend of analysts raising their expectations for the stock recently, bringing the average target across all firms to about 285 dollars. While the firm did not change its overall rating, the higher target suggests more confidence in the company's ability to grow its clinical research and data business. The stock currently trades around 270 dollars.

Sources: [Stifel Nicolaus](https://thefly.com/ajax/news_get.php?id=4441202)

## IQVIA Holdings Inc. earnings

In Q3 2026, reported on October 27, 2026, IQVIA Holdings Inc. posted earnings of $3.34 per share against $3.26 expected, and revenue of $4.4 billion against $4.4 billion expected.

The next earnings report is expected on February 4, 2027. Analysts expect $3.60 per share. Revenue is expected around $4.5 billion.

What to watch: Whether new contract signings keep growing at double-digit rates, which would confirm that drug companies are ramping up their research spending again.

## Recent analyst activity on IQV

- October 29, 2026: TD Cowen Kept rating at Buy, raised target from $288. Price target: $307.00.
- October 28, 2026: JP Morgan Kept rating at Overweight.
- October 28, 2026: Truist Securities Kept rating at Buy.
- October 28, 2026: Baird Kept rating at Outperform.
- October 28, 2026: Evercore ISI Group Kept rating at Outperform.
- October 28, 2026: Truist Financial Raised target from $329. Price target: $346.00.

## What's ahead for IQVIA Holdings Inc.

- February 4, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/IQV
